Exomics and immunogenics

References

• Soria JC, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): Additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). ECCO ESMO Congress 2013; abstract 3408.
   Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443 - 54; http://dx.doi.org/10.1056/NEJMoa1200690; PMID: 22658127
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134 - 44; http://dx.doi.org/10.1056/NEJMoa1305133; PMID: 23724846
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455 - 65; http://dx.doi.org/10.1056/NEJMoa1200694; PMID: 22658128
   PubMed Web of Science ®Google Scholar
• Daniel C. Cho, Jeffrey Alan Sosman, Mario Sznol, Michael S. Gordon, Antoine Hollebecque, Omid Hamid, David F. McDermott, Jean-Pierre Delord, Ina Park Rhee, Ahmad Mokatri,, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31, 2013 (suppl; abstr 4505)
   Google Scholar
• Omid Hamid, Jeffrey Alan Sosman, Donald P. Lawrence, Ryan J. Sullivan, Nageatte Ibrahim, Harriet M. Kluger, Peter D. Boasberg, Keith Flaherty, Patrick Hwu, Marcus Ballinger, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol 31, 2013 (suppl; abstr 9010)
   Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252 - 64; http://dx.doi.org/10.1038/nrc3239; PMID: 22437870
   PubMed Web of Science ®Google Scholar
• Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012; 18:6580 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-12-1362; PMID: 23087408
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214 - 8; http://dx.doi.org/10.1038/nature12213; PMID: 23770567
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale A-L, et al, Australian Pancreatic Cancer Genome Initiative. ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain. Signatures of mutational processes in human cancer. Nature 2013; 500:415 - 21; http://dx.doi.org/10.1038/nature12477; PMID: 23945592
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science 2013; 339:1546 - 58; http://dx.doi.org/10.1126/science.1235122; PMID: 23539594
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011; 18:23 - 34; http://dx.doi.org/10.1128/CVI.00286-10; PMID: 21048000
   PubMed Web of Science ®Google Scholar
• Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, et al. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 2011; 60:1137 - 46; http://dx.doi.org/10.1007/s00262-011-1011-9; PMID: 21465316
   PubMed Web of Science ®Google Scholar
• Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 2011; 108:16723 - 8; http://dx.doi.org/10.1073/pnas.1110814108; PMID: 21933959
   PubMed Web of Science ®Google Scholar
• van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJA, Behjati S, Hilkmann H, El Atmioui D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013; 31:e439 - 42; http://dx.doi.org/10.1200/JCO.2012.47.7521; PMID: 24043743
   PubMed Web of Science ®Google Scholar
• Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, Castermans E, Thor Straten P, Blank C, Haanen JB, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009; 6:520 - 6; http://dx.doi.org/10.1038/nmeth.1345; PMID: 19543285
   PubMed Web of Science ®Google Scholar
• Andersen RS, Kvistborg P, Frøsig TM, Pedersen NW, Lyngaa R, Bakker AH, Shu CJ. Straten Pt, Schumacher TN, Hadrup SR. Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc 2012; 7:891 - 902; http://dx.doi.org/10.1038/nprot.2012.037; PMID: 22498709
   PubMed Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72:1081 - 91; http://dx.doi.org/10.1158/0008-5472.CAN-11-3722; PMID: 22237626
   PubMed Web of Science ®Google Scholar
• Pfeifer GP, You Y-H, Besaratinia A. Mutations induced by ultraviolet light. Mutat Res 2005; 571:19 - 31; http://dx.doi.org/10.1016/j.mrfmmm.2004.06.057; PMID: 15748635
   PubMed Web of Science ®Google Scholar
• Pleasance ED, Stephens PJ, O’Meara S, McBride DJ, Meynert A, Jones D, Lin M-L, Beare D, Lau KW, Greenman C, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463:184 - 90; http://dx.doi.org/10.1038/nature08629; PMID: 20016488
   PubMed Web of Science ®Google Scholar
• Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012; 150:1121 - 34; http://dx.doi.org/10.1016/j.cell.2012.08.024; PMID: 22980976
   PubMed Web of Science ®Google Scholar
• Chow MT, Möller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin Cancer Biol 2012; 22:23 - 32; http://dx.doi.org/10.1016/j.semcancer.2011.12.004; PMID: 22210181
   PubMed Web of Science ®Google Scholar
• Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res 2005; 571:185 - 205; http://dx.doi.org/10.1016/j.mrfmmm.2004.06.059; PMID: 15748647
   PubMed Web of Science ®Google Scholar
• Garrido F, Cabrera T, Aptsiauri N. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010; 127:249 - 56; PMID: 20178101
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; http://dx.doi.org/10.1126/scitranslmed.3003689; PMID: 22461641
   PubMed Web of Science ®Google Scholar